Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

• Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands

• Expecting Impactful Near-Term Launches, Including Fast-Acting Meloxicam and Low-Dose Estrogen Weekly Patch in the U.S., and Pitolisant and Effexor® for GAD in Japan

• Unlocking Long-Term Value Through Potential Blockbusters Selatogrel and Cenerimod

• Strong Cash Flow Generation Enabling Capital Return and Disciplined Business Development

• Providing Long-Term Targets for Sustained Growth Through 2030

PITTSBURGH, March 19, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will host its Investor Event today, where members of the executive leadership team will outline the Company's strategic vision, key drivers and financial framework expected to deliver sustained revenue and earnings growth through 2030.

"Over the past several years, we have taken decisive actions to strengthen the foundation of Viatris by simplifying the portfolio, strengthening the balance sheet and stabilizing the base business," said

. "Today, we are entering the next phase of our evolution. With a growing base business, multiple anticipated near-term launches, a promising innovative pipeline and the financial flexibility to pursue disciplined accretive business development, we believe Viatris is well positioned to deliver sustained revenue and earnings growth through the end of the decade while continuing to create value for patients and shareholders."

"Our diversified portfolio and strong cash flow generation provide significant financial flexibility to invest in growth while maintaining a disciplined capital allocation framework," said

. "We expect to have more than $11 billion in cash available for deployment through 2030, which would enable us to return capital to shareholders and pursue accretive business development to further strengthen our long-term growth profile."

During the event, the Company will highlight key elements supporting its long-term growth targets, including its:

• Strategic vision and priorities
• R&D capabilities and pipeline overview
• Commercial capabilities and building blocks of growth
• Portfolio strategy and business development
• Financial framework for accelerating shareholder value

The Company believes these elements collectively support its framework for delivering sustained revenue and earnings growth through 2030.

At the event, the Company will also outline its long-term financial targets through 2030, including the capital allocation framework intended to support its future growth.

For its Combined Long-Term Targets through 2030, the Company expects to deliver 5% to 6% Total Revenues CAGR, 7% to 8% Adjusted EBITDA CAGR, 9% to 10% Adjusted EPS CAGR and more than $3 billion in annual free cash flow in 2030. 

The Combined Long-Term Targets are comprised of the Company's Base Case Long-Term Targets and Potential Additional Drivers.

For its Base Case Long-Term Targets through 2030, Viatris expects its base business, supported by anticipated upcoming launches of value-added medicines, to deliver 3% to 4% Total Revenues CAGR, 4% to 5% Adjusted EBITDA CAGR, including operating leverage from the cost savings resulting from its Enterprise-Wide Strategic Review, 6% to 7% Adjusted EPS CAGR, including the benefit from future expected share repurchases, and more than $2.7 billion in annual free cash flow in 2030.

As part of its recently completed Enterprise-Wide Strategic Review, Viatris identified approximately $650 million in gross cost savings over a three-year period, with up to $250 million expected to be reinvested in the Company.

Potential Additional Drivers include expected growth from accretive business development and the potential launches of selatogrel and cenerimod.

The Company expects more than $11 billion in cash available for deployment through 2030 under its Base Case Long-Term Targets and has assumed that approximately 50% of the cash available for deployment through 2030 will be allocated to disciplined accretive business development.

A live webcast of the Investor Event will begin today at 10:00 a.m. ET and can be accessed on the Company's website at investor.viatris.com. Presentation materials and a replay of the webcast will also be available on the Company's website.

Refers to Total Revenues, Adjusted EBITDA and Adjusted EPS.

Our 2026 financial guidance and long-term financial targets are based on the following budgeted exchange rates: Euro ($/EUR) 0.87, China Renminbi ($/CNY) 7.19, Japanese Yen ($/JPY) 144.35, and Indian Rupee ($/INR) 85.80.

Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a dynamic portfolio that spans generics, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai, China, and Hyderabad, India.

This press release includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("U.S. GAAP"). These non-GAAP financial measures, including, but not limited to, adjusted EBITDA, free cash flow, and adjusted EPS are presented in order to supplement investors' and other readers' understanding and assessment of the financial performance of Viatris. Free cash flow refers to U.S. GAAP net cash provided by operating activities less capital expenditures. Adjusted EBITDA refers to as U.S. GAAP net earnings (loss) adjusted for income tax provision (benefit), interest expense and depreciation and amortization (to calculate EBITDA) and further adjusted for share-based compensation expense, litigation settlements and other contingencies, net, loss on divestitures of businesses, impairment of goodwill and restructuring, acquisition and divestiture related and other special items. Adjusted EPS refers to adjusted net earnings divided by the weighted average number of diluted shares of common stock outstanding. Investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with U.S. GAAP.

The Company is not providing forward-looking information for U.S. GAAP net (loss) earnings, EPS or U.S. GAAP net cash provided by operating activities or a quantitative reconciliation of its long-term targets for adjusted EBITDA CAGR, adjusted EPS CAGR and free cash flow to their most directly comparable U.S. GAAP measures, U.S. GAAP net earnings (loss) CAGR, EPS CAGR and U.S. GAAP net cash provided by operating activities, respectively, because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items, including integration, acquisition and divestiture-related expenses, restructuring expenses, asset impairments, litigation settlements, future share repurchases, and other contingencies, such as changes to contingent consideration, acquired IPR&D and certain other gains or losses, including for the fair value accounting impact for equity investments, as well as related income tax accounting because certain of these items have not occurred, are out of the Company's control and/or cannot be reasonably predicted without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the relevant periods.

SOURCE Viatris Inc.